Lotze W, Richter P, Sarembe B
Zentralbl Gynakol. 1987;109(8):532-9.
Between 1978 and 1984 43 patients with advanced ovarian carcinomas got intra-arterially MTX and 5-FU after being operated, later they received systemically a CMFV chemotherapy (therapy arm A). 42 patients were treated systemically only with a CMFV combination. The results and complications of both types of treatment were evaluated according to theoretical and technical basis of the intraarterial infusion. The intra-arterial chemotherapy led to a significant better rate of remission (74 per cent in therapy arm A compared with 62 per cent in therapy arm B) because of a rapid induction of remission. The cumulative survival time was significantly extended to 27 months compared with 16 months after systemic therapy only.
1978年至1984年间，43例晚期卵巢癌患者术后接受了甲氨蝶呤和5-氟尿嘧啶的动脉内注射，随后他们接受了CMFV全身化疗（治疗组A）。42例患者仅接受CMFV联合全身治疗。根据动脉内灌注的理论和技术基础，对两种治疗方式的结果和并发症进行了评估。由于缓解诱导迅速，动脉内化疗导致缓解率显著提高（治疗组A为74%，治疗组B为62%）。与仅接受全身治疗后的16个月相比，累积生存时间显著延长至27个月。
